FDA Approves Therapy for Cerebral Folate Deficiency - Takeaways - MDSpire

FDA Approves Therapy for Cerebral Folate Deficiency

Decision addresses a rare neurologic disorder linked to folate transport impairment.

  • By

  • Kathryn Wighton

  • March 10, 2026

  • 2 min

Share

  • 1

    The FDA has approved Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency in patients with a confirmed FOLR1 variant.

  • 2

    This approval is the first FDA-sanctioned treatment for cerebral folate deficiency linked to FOLR1 variants, a rare genetic disorder.

  • 3

    Cerebral folate deficiency can lead to severe developmental delays, movement disorders, seizures, and other neurologic complications.

  • 4

    The approval was based on a systematic review of literature demonstrating clinical benefits of Wellcovorin compared to disease natural history.

  • 5

    Adverse reactions to leucovorin may include pruritus, rash, dyspnea, and anaphylaxis, requiring immediate medical attention.

Original Source(s)

FDA Approves Therapy for Cerebral Folate Deficiency

  • by Kathryn Wighton

  • March 10, 2026

Related Content

Aid in Dying Nears One Third of US

New laws in New York and Illinois will soon make medical aid in dying available to nearly one-third of Americans.

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.